Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SmithKline, Bayer Subpoenaed In Medicaid Repackaging Investigation

Executive Summary

A Boston grand jury is conducting an investigation of Kaiser's prescription drug repackaging operations as a potential avenue around the Medicaid "best price" rebate system.

You may also be interested in...



GSK, Bayer Will Audit Sales Contracts Under “Best Price” Rebate Settlement

Bayer will use an outside auditing firm to review its payments to managed care companies to ensure that the company is not disguising rebate payments

GSK, Bayer Will Audit Sales Contracts Under “Best Price” Rebate Settlement

Bayer will use an outside auditing firm to review its payments to managed care companies to ensure that the company is not disguising rebate payments

Bayer To Pay $257.2 Mil. In Medicaid Rebate Settlement

Bayer expects a Medicaid rebate settlement with the Boston U.S. attorney's office to involve a fine totaling about 10% of its annual North American pharmaceutical sales

Related Content

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel